Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the launch of IDEXX Cancer Dx, a first-of-its-kind diagnostic panel with ... Cancer Dx with lymphoma delivers ...

Stem cells were successfully harvested ... A previous study reported a 23-year-old female patient with ALK+ LBCL who was misdiagnosed with anaplastic large cell lymphoma due to a diffuse expression of ...

The IDEXX Cancer Dx panel features ... Actionable next steps: IDEXX Cancer Dx with lymphoma delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be ...

The IDEXX Cancer Dx panel features: Accuracy ... Actionable next steps: IDEXX Cancer Dx with lymphoma delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be ...

has made a major breakthrough in treating a common and challenging form of cancer called diffuse large B-cell lymphoma (DLBCL). In a clinical trial known as EPCORE NHL-2, the researchers showed ...

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information ...